Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Low Price/Cash Ratio Value Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Anaxagoras who wrote (151)	5/28/1999 3:43:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 1931

A good thing Cell Therapeutics on that list never appeared, hmmmmm. Dangers in these stocks are many. Of the the dark side, one must be, ever mindful, mmmmhmmm. {:-)} Recently Dave added SEPR and INCY I think to the list, plus Sibia will be getting an infusion from LLY in a recent deal, that one looks pretty good to me now. Trouble is, although I'd like to buy all three--Especially Sepracor, my plans are all messed up with SEPR having plunged before my microcaps have moved up much. So I guess for now I will just, er, stay on target...and wait some more. That was quite a grenade on CTIC today, wow. Glad I didn't have any. If I can navigate through the minefield without anything like that happening, I'll be in good shape. Low price/cash in biotech might be more dangerous than I had thought, but I'll be damned if I'm going to go start buying gold and oil outfits, heheh, I did that for awhile, boring.